+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019

  • ID: 4900077
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 86 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Extend Biosciences Inc
  • Helsinn Group
  • MORE
Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019

Summary

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 2, 10 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Metabolic Disorders, Toxicology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Hormonal Disorders, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Obesity, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Gastroparesis, Endocrine Gland Disorders, Fatigue, Growth Hormone Deficiency, Ischemia, Sepsis, Traumatic Brain Injury and Turner Syndrome.

The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Extend Biosciences Inc
  • Helsinn Group
  • MORE
Introduction
Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Extend Biosciences Inc
Helsinn Group
Lumos Pharma Inc
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
TheraSource LLC
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-418 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
livoletide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2019: Millendo closes enrolment for first part of livoletide’s ZEPHYR trial
Nov 07, 2019: Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019
Sep 26, 2019: Millendo Therapeutics to present at Prader-Willi Syndrome Conferences
Aug 01, 2019: UAB and Children's of Alabama to investigate new treatment for patients with Prader-Willi syndrome
May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
May 08, 2019: Millendo Therapeutics announces 21st European Congress of Endocrinology 2019 presentations on Livoletide for Prader-Willi syndrome
Mar 19, 2019: Millendo Therapeutics initiates pivotal Phase 2b/3 clinical study of livoletide for the treatment of Prader-Willi Syndrome
Mar 14, 2019: Millendo Therapeutics announces ENDO 2019 presentation on livoletide for Prader-Willi Syndrome
Mar 07, 2019: Helsinn initiates two new global Phase III studies with anamorelin
Jan 16, 2019: Aeterna Zentaris receives european marketing clearance for macimorelin
Nov 27, 2018: ONO submits an application for manufacturing and marketing approval of Anamorelin (ONO-7643), a ghrelin receptor agonist, for the treatment of cancer cachexia in Japan
Nov 15, 2018: Aeterna Zentaris receives positive CHMP opinion for Macimorelin for the treatment of Growth Hormone Deficiency
Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018
Sep 12, 2018: Extend Biosciences receives an SBIR supplemental award
Jun 28, 2018: URI drug study produces ‘promising therapy’ for alcohol abuse
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aeterna Zentaris Inc, H2 2019
Pipeline by Allergan Plc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Extend Biosciences Inc, H2 2019
Pipeline by Helsinn Group, H2 2019
Pipeline by Lumos Pharma Inc, H2 2019
Pipeline by Millendo Therapeutics Inc, H2 2019
Pipeline by Oxeia Biopharmaceuticals Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by RaQualia Pharma Inc, H2 2019
Pipeline by TheraSource LLC, H2 2019
Pipeline by Zeria Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Extend Biosciences Inc
  • Helsinn Group
  • Lumos Pharma Inc
  • Millendo Therapeutics Inc
  • Oxeia Biopharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • TheraSource LLC
  • Zeria Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll